-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Npx+0gEGqUAa9sLLzO207ln3Y5U5oJz78p7U6FAIPp7R+AnmXG6H62TjpXXJ58gK nRhMFL6w2Zy6DKhCVVN4zw== 0000947871-02-002403.txt : 20021209 0000947871-02-002403.hdr.sgml : 20021209 20021209165226 ACCESSION NUMBER: 0000947871-02-002403 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20021209 GROUP MEMBERS: MERLIN BIOMED GROUP, LLC GROUP MEMBERS: MERLIN BIOMED II, L.P. GROUP MEMBERS: MERLIN BIOMED III, L.P. GROUP MEMBERS: MERLIN BIOMED INVESTMENT ADVISORS, LLC GROUP MEMBERS: MERLIN BIOMED, L.P. GROUP MEMBERS: STUART T. WEISBROD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENAERA CORP CENTRAL INDEX KEY: 0000880431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133445668 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-42170 FILM NUMBER: 02852582 BUSINESS ADDRESS: STREET 1: 5110 CAMPUS DR CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: 6109415231 MAIL ADDRESS: STREET 1: 5110 CAMPUS DRIVE CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 FORMER COMPANY: FORMER CONFORMED NAME: MAGAININ PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MERLIN BIOMED GROUP LLC CENTRAL INDEX KEY: 0001106843 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 237 PARK AVE STREET 2: STE 801 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2128087425 MAIL ADDRESS: STREET 1: 237 PARK AVE STREET 2: STE 801 CITY: NEW YORK STATE: NY ZIP: 10017 SC 13D/A 1 sch13da_120902.txt GENERAL STATEMENT OF BENEFICIAL OWNERSHIP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - -------------------------------------------------------------------------------- SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) GENAERA CORPORATION ------------------- (Name of Issuer) Common Stock ------------------------------ (Title of Class of Securities) 36867G100 ---------------- (CUSIP Number) Norman Schleifer Merlin BioMed Group 230 Park Avenue, Suite 928 New York, NY 10169 Telephone: (646) 227-5200 --------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Richard Metsch, Esq. Shearman & Sterling 599 Lexington Avenue New York, New York 10022 Telephone: (212) 848-4000 December 2, 2002 ------------------ (Date of Event which Requires Filing of this Statement) - -------------------------------------------------------------------------------- If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f), or 13d-1(g), check the following box |_|. Check the following box if a fee is being paid with this Statement |_|. CUSIP No. 36867G100 (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person MERLIN BIOMED GROUP, LLC --------------------------------------------------------------------------- --------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions) |X| (a) ----------------------------------------------------------------------- |_| (b) ----------------------------------------------------------------------- ----------------------------------------------------------------------- (3) SEC Use Only -------------------------------------------------------------- --------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC ----------------------------------------- - -------------------------------------------------------------------------------- (5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e). |_| --------------------------------------------------------------------------- (6) Citizenship or Place of Organization Delaware --------------------------------------- --------------------------------------------------------------------------- - ------------------- Number of (7) Sole Voting Power 0 Shares -------------------------- Beneficially (8) Shared Voting Power 958,000 Owned by ------------------------ Each (9) Sole Dispositive Power 0 Reporting --------------------- Person With (10) Shared Dispositive Power 958,000 ------------------- - ------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 958,000 -------------- --------------------------------------------------------------------------- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |_| --------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) 2.68%* ------------------------- --------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) CO -------------------------------- 2 CUSIP No. 36867G100 *Merlin BioMed Group, L.L.C. ("MBG") is the general partner of Merlin BioMed, L.P. ("MBLP"), Merlin BioMed II, L.P. ("MBII") and Merlin BioMed III, L.P. ("MBIII"). As general partner, MBG has the shared power to vote or direct the vote and to dispose or direct the disposition of all 2,215,000 shares of Common Stock owned by MBLP, MBII and MBIII. MBG disclaims beneficial ownership of the shares of Common Stock referred to in this Statement, and the filing of this Statement shall not be construed as an admission that MBG is, for the purposes of Section 13(d) or 13(g) of the Act, the beneficial owner of any shares of Common Stock covered by this Statement. (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person MERLIN BIOMED INVESTMENT ADVISORS, LLC (on behalf of three managed accounts) --------------------------------------------------------------------------- --------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions) |X| (a) ----------------------------------------------------------------------- |_| (b) ----------------------------------------------------------------------- ----------------------------------------------------------------------- (3) SEC Use Only -------------------------------------------------------------- --------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC ----------------------------------------- --------------------------------------------------------------------------- (5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e). |_| --------------------------------------------------------------------------- (6) Citizenship or Place of Organization Delaware - ------------------- Number of (7) Sole Voting Power 0 Shares ---------------------------- Beneficially (8) Shared Voting Power 1,012,000 Owned by ------------------------- Each (9) Sole Dispositive Power 0 Reporting ----------------------- Person With (10) Shared Dispositive Power 1,012,000 --------------------- - ------------------- --------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 1,012,000 --------------- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |_| --------------------------------------------------------------------------- 3 CUSIP No. 36867G100 (13) Percent of Class Represented by Amount in Row (11) 2.89% ------------------------- --------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) IA -------------------------------- (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person MERLIN BIOMED, L.P. --------------------------------------------------------------------------- --------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions) |X| (a) ----------------------------------------------------------------------- |_| (b) ----------------------------------------------------------------------- ----------------------------------------------------------------------- (3) SEC Use Only -------------------------------------------------------------- --------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC ----------------------------------------- (5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e). |_| --------------------------------------------------------------------------- (6) Citizenship or Place of Organization Delaware --------------------------------------- --------------------------------------------------------------------------- - ------------------- Number of (7) Sole Voting Power 0 Shares ---------------------------- Beneficially (8) Shared Voting Power 482,022 Owned by ------------------------- Each (9) Sole Dispositive Power 0 Reporting ----------------------- Person With (10) Shared Dispositive Power 482,022 --------------------- - ------------------- --------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 482,022 --------------- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |_| --------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) 1.35% ------------------------- --------------------------------------------------------------------------- 4 CUSIP No. 36867G100 (14) Type of Reporting Person (See Instructions) PN -------------------------------- (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person MERLIN BIOMED II, L.P. ---------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions) |X| (a) ----------------------------------------------------------------------- |_| (b) ----------------------------------------------------------------------- (3) SEC Use Only -------------------------------------------------------------- --------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC ----- --------------------------------------------------------------------------- (5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e). |_| --------------------------------------------------------------------------- (6) Citizenship or Place of Organization Delaware --------------------------------------- - -------------------------------------------------------------------------------- - ------------------- Number of (7) Sole Voting Power 0 Shares ---------------------------- Beneficially (8) Shared Voting Power 236,500 Owned by ------------------------- Each (9) Sole Dispositive Power 0 Reporting ----------------------- Person With (10) Shared Dispositive Power 236,500 --------------------- - ------------------- --------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 236,500 --------------- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |_| --------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) .66% ------------------------- --------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) PN -------------------------------- 5 CUSIP No. 36867G100 (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person MERLIN BIOMED III, L.P. ----------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions) |X| (a) ----------------------------------------------------------------------- |_| (b) ----------------------------------------------------------------------- (3) SEC Use Only -------------------------------------------------------------- --------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC ------ --------------------------------------------------------------------------- (5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e). |_| --------------------------------------------------------------------------- (6) Citizenship or Place of Organization Delaware -------------------------------------- --------------------------------------------------------------------------- - ------------------- Number of (7) Sole Voting Power 0 Shares ---------------------------- Beneficially (8) Shared Voting Power 239,478 Owned by ------------------------- Each (9) Sole Dispositive Power 0 Reporting ----------------------- Person With (10) Shared Dispositive Power 239,478 --------------------- - ------------------- --------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 239,478 --------------- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |_| --------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) .67 % ------------------------- --------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) PN -------------------------------- 6 CUSIP No. 36867G100 (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person STUART T. WEISBROD ------------------ --------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions) |X| (a) ----------------------------------------------------------------------- |_| (b) ----------------------------------------------------------------------- ----------------------------------------------------------------------- (3) SEC Use Only -------------------------------------------------------------- --------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC ----------------------------------------- --------------------------------------------------------------------------- (5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e). |_| --------------------------------------------------------------------------- (6) Citizenship or Place of Organization United States -------------------------------------- --------------------------------------------------------------------------- - ------------------- Number of (7) Sole Voting Power 100,000 Shares ---------------------------- Beneficially (8) Shared Voting Power 2,215,000 Owned by ------------------------- Each (9) Sole Dispositive Power 100,000 Reporting ----------------------- Person With (10) Shared Dispositive Power 2,215,000 --------------------- - ------------------- --------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 2,215,000 --------------- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |X| --------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) 6.2%* ------------------------- (14) Type of Reporting Person (See Instructions) IN -------------------------------- 7 CUSIP No. 36867G100 *The 2,215,000 shares of Common Stock include 145,000 shares of Common Stock held by the members of Stuart T. Weisbrod's immediate family. Stuart T. Weisbrod disclaims beneficial ownership of all shares of Common Stock except for 100,000 shares of Common Stock, and the filing of this Statement shall not be construed as an admission that Stuart T. Weisbrod is, for the purposes of Section 13(d) or 13(g) of the Act, the beneficial owner of any shares of Common Stock of the Issuer covered by this Statement except for 100,000 shares of Common Stock. This Amendment No. 2 (this "Second Amendment") amends and supplements Schedule 13D Amendment No. 1 filed with the Securities and Exchange Commission on November 21, 2001 ("Amendment No. 1") jointly filed by Merlin BioMed Group, LLC, a Delaware limited liability company, Merlin BioMed Investment Advisors, LLC, a Delaware limited liability company (on behalf of three managed accounts), Merlin BioMed, L.P., a Delaware limited partnership, Merlin BioMed II, L.P., a Delaware limited partnership, Merlin BioMed III, L.P., a Delaware limited partnership, and Stuart T. Weisbrod, and is filed to reflect information required by Rule 13d-2 under the Securities Exchange Act of 1934, as amended, with respect to common stock, par value $0.001 per share (the "Common Stock"), of Genaera Corporation, a Delaware Corporation (the "Issuer"). Capitalized terms used in this First Amendment and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D. Item 4. Purpose of Transaction. ---------------------- To reduce the size of the filer's position because filer does not believe that management of the Issuer has taken necessary steps to enhance shareholder value. Item 7. Material to Be Filed as Exhibits. -------------------------------- The Schedule of sales of shares of Common Stock within the past 60 days. 8 CUSIP No. 36867G100 After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct. December 9, 2002 MERLIN BIOMED GROUP, L.L.C. /s/ Stuart T. Weisbrod ---------------------- Name: Stuart T. Weisbrod Title: Managing Member MERLIN BIOMED INVESTMENT ADVISORS, L.L.C. /s/ Stuart T. Weisbrod ---------------------- Name: Stuart T. Weisbrod Title: Managing Member MERLIN BIOMED, L.P. /s/ Stuart T. Weisbrod ---------------------- Name: Stuart T. Weisbrod Title: Managing Member of General Partner MERLIN BIOMED II, L.P. /s/ Stuart T. Weisbrod ---------------------- Name: Stuart T. Weisbrod Title: Managing Member of General Partner MERLIN BIOMED III, L.P. /s/ Stuart T. Weisbrod ---------------------- Name: Stuart T. Weisbrod Title: Managing Member of General Partner /s/ Stuart T. Weisbrod ---------------------- Name: Stuart T. Weisbrod 9 Exhibit
- ------------------------------------------------------------------------------------------------------------------------------------ Item Prt Action Trade Date Amount Security Price Broker Gross Total Comm SEC Net - ------------------------------------------------------------------------------------------------------------------------------------ 1MB2LP Sell 11/21/2002 10700GENR 0.45JOST 4815 0 0.17 4814.83 2MB3LP Sell 11/21/2002 5700GENR 0.45JOST 2565 0 0.09 2564.91 3MBINTL Sell 11/21/2002 15800GENR 0.45JOST 7110 0 0.24 7109.76 4MBLP Sell 11/21/2002 20800GENR 0.45JOST 9360 0 0.32 9359.68 5SW Sell 11/25/2002 100000GENR 0.43burl 43000 500 1.44 42498.56 6MB2LP Sell 11/26/2002 22600GENR 0.45JOST 10170 226 0.34 9943.66 7MBINTL Sell 11/26/2002 33700GENR 0.45JOST 15165 337 0.51 14827.49 8MBLP Sell 11/26/2002 43700GENR 0.45JOST 19665 437 0.66 19227.34 9MB2LP Sell 12/2/2002 112200GENR 0.45JOST 50490 0 1.69 50488.31 10MBINTL Sell 12/2/2002 167000GENR 0.45JOST 75150 0 2.51 75147.49 11MBLP Sell 12/2/2002 216600GENR 0.45JOST 97470 0 3.25 97466.75 12401k Sell 12/3/2002 25000GENR 0.5038GARG 12595 250 0.42 12344.58
-----END PRIVACY-ENHANCED MESSAGE-----